Related Experiment Video

Updated: Jun 17, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Is there a role for erythropoietin in cardiovascular disease?

Georgia Vogiatzi1, Alexandros Briasoulis, Dimitris Tousoulis

  • 1Athens University Medical School, Hippokration Hospital, First Cardiology Unit, Vasilissis Sofias 114, 115 28, Athens, Greece.

Expert Opinion on Biological Therapy
|December 24, 2009
PubMed

Insights

Erythropoietin (EPO) shows promising non-erythropoietic effects for cardiovascular diseases like heart failure. Further clinical studies are needed to confirm its benefits in treating coronary artery and peripheral artery diseases.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Regenerative Medicine

Background:

  • Cardiovascular diseases (CVDs) remain a leading cause of mortality despite medical advancements.
  • Novel therapies targeting myocardial ischemia and heart failure are crucial.
  • Recent technological progress facilitates the translation of new therapies to clinical practice.

Purpose of the Study:

  • To review current experimental and clinical trials on erythropoietin (EPO) in cardiovascular diseases.
  • To explore the non-erythropoietic, beneficial effects of EPO in a clinical cardiovascular context.

Main Methods:

  • Comprehensive review of existing literature on erythropoietin (EPO) in cardiovascular research.
  • Analysis of preclinical and clinical trial data.

Main Results:

  • Preclinical studies indicate encouraging non-erythropoietic effects of EPO.
  • EPO demonstrates potential therapeutic benefits beyond its red blood cell-stimulating properties.

Conclusions:

  • Erythropoietin's non-erythropoietic effects show significant promise in preclinical cardiovascular models.
  • Further clinical investigation is essential to establish EPO's role in managing coronary artery disease, heart failure, and peripheral artery disease.
Abstract

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Related Concept Videos

Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...